凯息平口服液对H_(22)荷瘤小鼠的抑瘤生长作用及抑瘤机理探讨

Discussion on the Tumor Growth Inhibition Action and Inhibitory Mechanism of Kaixiping Oral Fluid on H_(22 ) Tumorigenic Mouse

凯息平口服液对小鼠移植性H2 2 实体瘤有明显的抑瘤生长作用 ,2 7.0、18.0、9.0g/kg剂量的抑瘤率分别 4 7.6 %、4 7.8%和 33.8% ;对H2 2 腹水癌小鼠有一定的延长生存期的作用 ,强于阳性对照药复方天仙胶囊 ,且没有氟尿嘧啶 (5 FU)所表现的毒副作用。对体外培养的H2 2 细胞有一定程度的抑制作用 ,最低有效药物浓度可达 2 5mg/L ,抑制作用可维持 4 8h以上。但对培养的脾T细胞 ,其剂量达 80 0mg/L时才表现出抑制增殖的作用。表明凯息平口服液对肿瘤细胞有独特的抑制作用 ,绝非细胞毒所致。实验还表明 :凯息平口服液能增强荷瘤鼠的T、B淋巴细胞增殖能力 ;对自然杀伤细胞 (NK)的活性也有明显的促进作用 ,同时明显增强腹腔巨噬细胞 (MΦ)的吞噬活性 ,显示了其在抗肿瘤免疫中具有重要的作用。

Kaixiping oral fluid (KXP) has a markedly growth inhibition action on transplantation H22 tumor in mouse. The tumor inhibitory rates at the dosage of 27.0, 18.0 and 19.0g/kg are respectively 47.6%, 47 8%and 33 8%. The action of prolonging survival time of the mouse with H 22 ascites tumor is stronger than the complex prescription 'Tianxian' capsule which was taken as positive contrasting drug, and has no toxic_side effect expressed by 5 Fu. It has some inhibitory action on the H 22 cell cultured in vitro, which the lowest effective drug concentration can reach 25mg/L and the time can last more than 48h. But for the T splenocyte, only when the dosage reaches 800mg/L does the proliferation inhibitory action work. It indicate that KXP has special inhibitory action on the tumor cell, which can not be induced by cytotoxicity. This experiment also show KXP can enhance proliferative ability of the T, B lymphocyte, markedly reinforce the activity of natural killer cell (NK) and the phagocytic activity of celiac macrophagocyte (MΦ), which prove KXP's importance in the antineoplastic immunity.